Table 2

Etanercept data

Total population
COBRA (n=81)COBRA-light (n=81)RR (95% CI)*p Value
Etanercept start required, total patients (DAS44 ≥1.6), n (%)47 (59)61 (75)1.67 (1.05 to 2.65)0.03
 Based on DAS44 ≥1.6 and <2.4, n (%)29 (62)31 (51)1.03 (0.81 to 1.31)0.79
 Based on DAS44 ≥2.4, n (%)18 (38)30 (49)1.23 (1.00 to 1.51)0.04
Actual started, total (DAS44 ≥1.6), n (%)27 (57)40 (66)1.30 (0.82 to 2.08)0.04
 Based on DAS44 ≥1.6 and <2.4, n (%)15 (56)18 (45)0.88 (0.54 to 1.42)0.59
 Based on DAS44 ≥2.4, n (%)12 (44)22 (55)1.24 (0.76 to 2.00)0.40
Activity at intended start: etanercept actual starters vs non-starters
COBRA (n=50)COBRA-light (n=61)
Starters (n=27)Non-starters (n=22)p ValueStarters (n=40)Non-starters (n=21)p Value
DAS442.44 (0.7)2.24 (0.6)0.302.66 (0.9)2.05 (0.5)<0.01
Tender joints8.5 (5.9)9.3 (11.9)0.779.4 (9.5)2.8 (1.6)<0.01
Swollen joints5.0 (4.0)4.2 (9.4)0.736.4 (7.5)1.6 (1.8)<0.01
HAQ†0.87 (0.7)0.69 (0.6)0.450.98 (0.7)0.61 (0.6)0.10
ESR, mm/h, median (IQR)6.0 (3.0–9.0)8.5 (4.0–14.0)0.1013.0 (3.3 to 22.8)18.5 (6.5 to 24.5)0.43
CRP, mg/L, median (IQR)2.8 (1.8–5.5)2.5 (2.0–9.0)0.904.0 (1.0 to 10.0)2.8 (1.8 to 5.0)0.43
Patient global assessment, by VAS, mm41.4 (23.4)46.7 (24.0)0.4543.3 (25.5)28.7 (22.3)0.03
  • Data are expressed as mean (SD) unless otherwise stated.

  • *RR analyses.

  • †HAQ score was only assessed at week 26.

  • COBRA, Combinatietherapie Bij Reumatoïde Artritis; CRP, C-reactive protein; DAS44, 44-joint count Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; RR, relative risk; VAS, visual analogue scale.